Cantor Fitzgerald analyst Charles Duncan maintained a Buy rating on Inovio Pharmaceuticals (INO – Research Report) today and set a price target of $13.00. The company’s shares closed last Wednesday at $7.13.
According to TipRanks.com, Duncan is a 5-star analyst with an average return of 7.2% and a 47.8% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Stealth Biotherapeutics, and ACADIA Pharmaceuticals.
Currently, the analyst consensus on Inovio Pharmaceuticals is a Moderate Buy with an average price target of $10.25, representing a 42.0% upside. In a report issued on March 31, H.C. Wainwright also reiterated a Buy rating on the stock with a $13.00 price target.
The company has a one-year high of $19.37 and a one-year low of $1.92. Currently, Inovio Pharmaceuticals has an average volume of 29.84M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system’s tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.